Skip to main content
. Author manuscript; available in PMC: 2018 Aug 12.
Published in final edited form as: Cancer Immunol Res. 2017 Jun 19;5(8):618–629. doi: 10.1158/2326-6066.CIR-17-0051

Figure 1.

Figure 1

Mass spectrometric identification of SLC45A2-derived peptides from melanoma cell lines. A, Experimental strategy to identify melanoma tumor-specific peptides from melanoma cell lines. B and C, Mass spectra of HLA-A*0201- and HLA-A*2402–restricted tumor cell–derived and synthetic SLC45A2 peptides. B, Peptide eluted from HLA-A*0201+ melanoma cells (top) and HLA-A*0201–transduced Mel888 melanoma cells (middle) showed a corresponding MS fragmentation pattern for the synthetic peptide SLYSYFQKV (bottom). C, Peptide eluted from HLA-A*2402+ melanoma cells (top) and HLA-A*2402–transduced Mel888 melanoma cells (middle) showed a corresponding fragmentation pattern for the synthetic peptide SYIGLKGLYF (bottom).